Cyclopharm Ltd (Cyclopharm) is a manufacturer and provider of radiopharmaceutical products and medical equipment to the medical equipment industry. Its products find application in lung imaging, cancer, cardiac and brain imaging and others. The company prioritizes the development of nuclear pulmonology imaging particularly with its flagship offering, Technegas.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Cyclopharm’s R&D enables it to develop new products. The company conducts R&D to develop new radiopharmaceutical products and to extend the use of its existing products in new indications related to respiratory disorders. The company focuses on expanding the use of Technegas, a diagnostic tool used in pulmonary care. The company is conducting ongoing research and trials to explore the potential of Technegas in addressing a broader spectrum of respiratory conditions and requirements, including Pulmonary Embolism (PE), Chronic Thromboembolic Pulmonary Hypertension (CTEPH), and Chronic Obstructive Pulmonary Disease (COPD). In FY2024, the company spent AUD0.4 million on its R&D activities, which as a percentage of revenue stood at 1.3%.